These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6489413)

  • 1. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
    Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Cabrini E; Fasoli A
    Pharmacol Res Commun; 1984 Aug; 16(8):809-20. PubMed ID: 6593751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
    Avogaro P; Bittolo Bon G; Belussi F; Pontoglio E; Cazzolato G
    Atherosclerosis; 1983 Apr; 47(1):95-100. PubMed ID: 6870993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of fenofibrate in hyperlipoproteinemias].
    Ducobu J
    Acta Clin Belg; 1980; 35(3):148-54. PubMed ID: 7456965
    [No Abstract]   [Full Text] [Related]  

  • 6. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
    Weisweiler P; Merk W; Jacob B; Schwandt P
    Eur J Clin Pharmacol; 1986; 30(2):191-4. PubMed ID: 3709644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
    Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
    Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
    Artery; 1985; 12(6):363-81. PubMed ID: 4051756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
    Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Grundy SM; Knopp RH; Lasser NL; Mellies MJ; Palmer RH; Samuel P
    Arteriosclerosis; 1986; 6(6):670-8. PubMed ID: 3535757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 14. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
    Ramjattan BR; Callaghan DJ; Theiss U
    Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D; Oschry Y; Fainaru M; Eisenberg S
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.